Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-04-25 Governance Information
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
内部控制制度
Governance Information Classification · 95% confidence The document is titled '内部控制制度' (Internal Control System) and is issued by the company's board of directors. It details the internal control policies, risk assessment, internal control activities, management of subsidiaries, fundraising usage, related party transactions, external guarantees, major investments, information disclosure, communication, and internal supervision. The document is comprehensive and lengthy (over 10,000 characters), containing detailed governance and control procedures rather than financial statements or audit results. It is not an announcement of a report but the actual internal control system document. This type of document aligns with Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices. Therefore, the appropriate classification is CGR with high confidence.
2023-04-25 Chinese
2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制自我评价报告' which translates to '2022 Annual Internal Control Self-Evaluation Report'. It is issued by the company's board and discusses the internal control evaluation for the fiscal year ending December 31, 2022. The content includes detailed descriptions of the company's internal control environment, risk assessment, control activities, and evaluation conclusions. It also references compliance with relevant laws and regulations, and the absence of significant internal control deficiencies. The document is comprehensive and contains substantive information about internal controls rather than just an announcement or summary. This type of report is typically classified as an Audit Report / Information (AR) because it focuses on internal control evaluation and audit-related information rather than full financial statements or annual performance (which would be 10-K), or other categories like management changes or earnings releases. The document length (over 10,000 characters) and detailed content confirm it is a full report, not a brief announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-25 Chinese
关于2023年向金融机构申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's plan to apply for a credit facility from financial institutions for the year 2023. It details the amount, purpose, and approval status of the credit application. There is no financial statement or detailed financial report included. The document is relatively short (943 characters) and serves as an update on financing activities rather than a full financial report. Therefore, it fits the category of Capital/Financing Update (CAP).
2023-04-25 Chinese
独立董事关于第三届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several company matters discussed at a board meeting, including the 2022 equity distribution plan, the use of raised funds, the 2023 remuneration plan for directors and senior management, and a share repurchase plan. It references compliance with laws and regulations and expresses agreement with these proposals to be submitted to the shareholders' meeting. The document is not a full financial report, earnings release, or regulatory filing but rather a formal opinion related to board meeting resolutions. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions from the board or senior management regarding company matters.
2023-04-25 Chinese
2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled '2022 年度独立董事述职报告' which translates to '2022 Annual Independent Directors' Report'. It details the independent directors' attendance, opinions, committee work, investor protection efforts, inspections, training, and other activities during the 2022 fiscal year. The content is a detailed report on the independent directors' duties and activities rather than a general annual report or financial statement. It is not an announcement or a brief summary but a substantive report on management and governance activities related to independent directors. This fits best under the category of Board/Management Information (MANG), which covers announcements about board members and senior management activities and reports. The document length is 3152 characters, which is relatively short but contains detailed content about board members' activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2023-04-25 Chinese
回购股份方案公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding a share repurchase plan by the company 四川梓橦宫药业股份有限公司. It includes specifics about the repurchase purpose, method, price limits, quantity, funding source, implementation period, and expected impact on the company's financials and share structure. It also discusses regulatory compliance and risks related to the repurchase. The content is focused on the company's plan to buy back its own shares and the related procedural and financial details. This matches the definition of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and plans. The document is not a full financial report, earnings release, or management discussion, nor is it a regulatory announcement or voting result. Therefore, the appropriate classification is POS with high confidence.
2023-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.